A trial vaccine for Covid-19 being developed by Oxford scientists could produce a greater antibody response in larger doses, a study involving pigs suggests.

The ChAdOx1 nCoV-19 vaccine, being developed by the University of Oxford, is currently undergoing human trials.

Work with the Purbright Institute in Woking to test the vaccine on pigs found that two doses of the trial vaccine resulted in a marked increase in neutralising antibodies that block infection.

Prof Simon Graham, lead author of the study, said: "While it remains to be determined what immune responses are required to effectively protect people against Covid-19, the demonstration that ChAdOx1 nCoV-19 induces both neutralising antibody and T cell responses is very encouraging."